![]() |
市場調查報告書
商品編碼
2103770
外科雷射市場:全球市場預測(2026-2032)Surgical Lasers Market - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,外科雷射市場將成長至 42.6 億美元,複合年成長率為 6.19%。
| 主要市場統計數據 | |
|---|---|
| 基準年(2025 年) | 28億美元 |
| 預計年份(2026年) | 29億美元 |
| 預測年份(2032年) | 42.6億美元 |
| 複合年成長率() | 6.19% |
外科雷射在眼科、皮膚科、泌尿系統、婦科、牙科、腫瘤科、心血管內科、耳鼻喉科以及微創手術等領域的精準醫療中正發揮核心作用。這些設備透過發射聚焦光能,例如二氧化碳雷射、Nd:YAG雷射、二極體雷射、鉺雷射、準分子雷射、钬雷射、铥雷射和飛秒雷射等,能夠實現高度可控的切開、消融、凝固、汽化、碎石、光凝和組織表面置換。其臨床價值與減少出血、提高手術視野、縮短切口路徑、透過合理選擇減少熱擴散以及增強與內視鏡、機器人和影像引導平台的兼容性密切相關。需求受多種因素影響,包括手術數量的增加、人口老化、白內障、良性前列腺增生、腎結石、皮膚病變、青光眼、糖尿病視網膜病變和慢性眼科疾病的盛行率上升,以及患者對微創治療和快速康復的渴望。監管、雷射安全標準、臨床醫生培訓、波長特異性適應症、眼瞼保護和維護品質仍然是影響其應用的關鍵因素。因此,外科雷射的現狀不僅取決於設備創新,還取決於循證臨床效用、與手術流程的整合以及醫療系統支援安全高效雷射手術的能力。
隨著醫療機構從獨立式能量設備轉向互聯互通、針對特定手術流程的平台,外科雷射領域正經歷變革性的轉變。隨著微創手術和門診手術的興起,緊湊型二極體雷射和固體雷射系統的重要性日益凸顯,而飛秒雷射和準分子雷射則繼續為高精度眼科應用提供支援。在泌尿系統,波長最佳化、光纖小型化、基於摩西效應的脈衝調製、铥光纖雷射的應用以及能量傳輸的改進等技術進步,已被證明對雷射碎石術和前列腺手術大有裨益。在皮膚科和整形外科領域,點陣照射、脈衝調製、冷卻技術以及針對不同膚質的個人化方案,正在推動手術的個人化發展。醫院和門診手術中心優先考慮那些能夠縮短手術時間、提供可重複治療效果並符合感染控制和設備使用規範的系統。同時,採購決策也日趨精細化,需要考慮整體擁有成本、光纖等耗材、服務合約、訓練要求、雷射煙霧管理、眼部安全措施以及與現有內視鏡和成像系統的兼容性。向價值醫療模式的轉變也促使供應商和醫療服務提供者透過同行評審的證據、真實世界的臨床表現以及手術效率、併發症減少和患者體驗等方面的可衡量改進來證明其臨床效益。
人工智慧 (AI) 正在開始影響外科雷射技術,其作用並非取代臨床醫生的決策,而是最佳化手術規劃、引導、監測和工作流程。 AI 驅動的影像分析可輔助眼科、皮膚科和腫瘤科的術前評估,幫助識別組織邊界、病變特徵、血管模式或治療區域。術中決策支援工具結合影像、感測器回饋和手術參數,可輔助組織辨識、熱控制、皮瓣偵測和安全警報,進而提高能量傳遞的精準度。在整合機器人和導航系統的雷射平台上,AI 可透過輔助軌跡規劃、防手震、深度估計和自動記錄來提高精度。預測性維護演算法可透過分析設備效能日誌、光纖使用模式、校準狀態和錯誤代碼來提高儀器可靠性,從而減少停機時間。然而,人工智慧技術的應用受到諸多限制,包括檢驗要求、網路安全義務、可解釋性預期、作為醫療設備的軟體所面臨的監管審查,以及需要反映不同患者群體、皮膚類型、眼部特徵和手術類型的多樣化臨床資料集。人工智慧在外科雷射領域的累積影響預計將在提高安全性、標準化技術、減少變異性、支援可審計性以及為臨床品管提供合法依據等方面最為顯著。
在亞太東南亞國協,醫院基礎設施的不斷完善、白內障和屈光矯正手術量的激增、醫療旅遊的快速發展以及皮膚科、牙科、耳鼻喉科和泌尿系統手術的普及,正推動著中國、印度、日本、韓國、澳大利亞和東協國家採用手術雷射技術。在北美,手術需求持續成長,眼科、皮膚科、泌尿系統、婦科和微創手術雷射技術已廣泛應用。這得歸功於先進的門診手術環境、針對特定手術的保險報銷機制、完善的雷射安全措施以及嚴格的監管合規性。在拉丁美洲,隨著私人醫療網路、整形外科中心、牙科診所和專科診所投資雷射系統,雷射技術的應用正在逐步推進,但價格、培訓機會、資金籌措和設備維護仍然是重要的阻礙因素。在歐洲,雷射技術的優點包括成熟的醫院體系、積極採納臨床指南以及監管機構對安全性、臨床評估、上市後監測和循證醫療設備性能的重視,其需求主要來自眼科、婦科、皮膚科、泌尿系統和泌尿科的應用。在中東,隨著專科醫院的建設、高品質外科手術的普及、對數位化手術室的投資以及政府主導的醫療現代化,雷射技術的應用正在取得進展,其需求主要集中在都市區和醫療旅遊中心。在非洲,情況則更為複雜,一些大型私立醫院和三級醫療機構已開始將雷射技術應用於眼科、泌尿系統、牙科和皮膚科,但更廣泛的應用取決於臨床醫生的培訓、可靠的基礎設施、資金籌措模式、轉診途徑以及維護服務的可及性。
在東協市場,受私立醫院網路擴張、醫療旅遊興起、城市地區專科診所增多以及眼科、牙科、泌尿系統和美容手術能力提升的推動,新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國的雷射手術需求日益成長。在海灣合作理事會(GCC)國家,得益於醫療保健多元化策略和針對都市區重症患者的醫療模式,透過投資專科醫院、數位化手術室以及高階皮膚科、眼科、婦科和泌尿系統服務,對先進雷射手術的需求強勁。在歐盟,隨著醫療設備法規的加強,監管合規性、臨床證據、醫療設備可追溯性和上市後監管受到重視,其應用與安全認證、性能監測和醫院採購標準密切相關。在金磚國家,雷射手術的應用環境正在多元化發展。在中國和印度,手術量龐大,醫院容量不斷擴大,製造業生態系統也不斷發展。在巴西和南非,需求主要體現在私立專科醫療機構和都市區三級醫療機構。在俄羅斯,眼科、泌尿系統、皮膚科和醫院外科的需求仍然強勁,儘管採購和取得途徑各不相同。在七國集團(G7)國家,外科雷射技術在現有專科領域的應用正在逐步推進,這通常得益於訓練有素的臨床醫生、先進的門診護理、臨床管治和更完善的品管系統。雖然北約成員國的醫療保健系統並非單一的醫療採購集團,但它們通用共同重視醫療保健的韌性、互通性、臨床安全、應急準備和先進的醫院基礎設施,這在國家醫保報銷機制和監管途徑允許的範圍內,可以間接地支持高精度外科技術的應用。
在美國,外科雷射技術已廣泛應用於眼科、皮膚科、泌尿科、泌尿系統、牙科、耳鼻喉科和門診手術等眾多領域,這得益於高密度的專科醫生、門診手術中心、法律規範以及健全的臨床培訓體系。在加拿大,醫院和專科診所正穩步推進雷射技術的應用,其採購趨勢受到各省醫療保健優先事項、安全標準、技術評估以及都市區地區醫療服務可近性等因素的影響。在墨西哥,私人醫療保健、跨境醫療保健以及眼科、牙科和美容手術的成長推動了雷射技術的進步,但資金籌措、培訓機會和服務覆蓋範圍限制了其更廣泛的應用。巴西是拉丁美洲雷射手術發展潛力最大的國家,擁有大規模的私人醫療保健體系、強大的皮膚科實力、對眼科的需求、完善的牙科服務能力以及不斷擴展的泌尿系統應用。在英國,外科雷射技術正透過公立醫院和私立診所應用,其應用受到循證評估、預算優先排序、臨床管治和規範的患者安全措施的影響。德國是一個技術先進的國家,其特點是擁有完善的醫院基礎設施、精準手術實踐以及在眼科、泌尿科、泌尿系統、婦科和皮膚科的廣泛應用。在法國,監管方面的應用主要體現在醫院採購、臨床品質標準以及由專家主導的眼科、皮膚科、婦科、耳鼻喉科和泌尿系統的應用。在俄羅斯,對雷射眼科和醫院手術的需求仍然強勁,但先進系統的可及性可能因地區、採購途徑和服務能力而異。在義大利和西班牙,雷射技術已在眼科、皮膚科、泌尿系統、牙科和婦科廣泛應用,這得益於專科診所網路和對微創治療的需求。中國醫療發展迅速,這得益於醫院容量的擴大、國產醫療設備的研發、手術量的激增以及對眼科、泌尿科、泌尿系統和美容手術的強勁需求。印度的外科手術需求遠未得到滿足,但私立醫院網路正在擴張,醫療旅遊業蓬勃發展,雷射技術在眼科、泌尿系統、牙科、皮膚科和婦科的應用也在增加。日本擁有高品質、技術導向的醫療環境,眼科、皮膚科、內視鏡手術和微創手術等醫療實踐蓬勃發展。在澳大利亞,手術雷射已在眾多先進醫院和專科診所得到應用,其普及程度受臨床醫生培訓、監管合規、醫保報銷以及區域醫療服務體係等因素的影響。在技術導向型醫院、醫療旅遊以及患者對微創手術的強烈需求的支持下,韓國在皮膚病學、美容醫學、眼科學、牙科和先進外科醫學領域展現出非常活躍的發展態勢。
行業領導者應優先考慮基於循證醫學的產品策略,使每種手術雷射平台都與明確的臨床適應症、檢驗的安全特性、每種波長的特定應用案例以及可衡量的工作流程優勢相匹配。製造商和經銷商應投資於臨床醫生教育、基於模擬的培訓、雷射安全認證支援、煙霧管理指導以及特定應用方案,以減少差異並加快部署。醫療機構應從總體擁有成本、光纖和耗材需求、應對力、校準需求、煙霧排放要求、眼部安全措施、與內視鏡和成像系統的整合以及人員能力要求等方面評估儀器。產品開發團隊應專注於緊湊的面積、直覺的介面、脈衝和能量精度、組織特異性預設、與冷卻和煙霧管理系統的兼容性、光纖耐久性以及數位化文件功能。旨在部署人工智慧驅動的雷射系統的機構必須建立透明的檢驗框架、網路安全措施、偏差評估流程、人工監督模型以及符合監管要求的證據包。區域策略不應依賴單一的全球商業化模式,而應綜合考慮報銷機制、基礎設施成熟度、治療內容、在地訓練能力和服務網路。最重要的是,領導者需要將手術雷射定位為更廣泛的精準手術生態系統的一部分,該生態系統涵蓋設備性能、手術培訓、病患安全和術後結果追蹤。
本執行摘要採用系統性的二手調查方法撰寫,重點在於檢驗的、資料支援的產業資訊。此方法整合了來自監管機構、認證醫療設備安全標準、臨床實踐指南、同行評審的醫學文獻、公共衛生統計資料、醫院採購考量、專業協會資源以及各外科專科採用趨勢記錄的資訊。分析著重於臨床應用、技術進步、區域醫療保健基礎設施、法規環境、手術流程以及推廣應用的促進因素和障礙。此分析方法排除了未經證實的預測、市場規模估算、市場佔有率和未來展望,而是專注於可驗證的促進因素,例如疾病負擔、外科技術的進步、門診實踐的擴展、雷射安全要求、培訓需求、設備維護和技術整合。透過醫療保健的可及性、專科接受能力、監管成熟度、報銷環境和服務基礎設施,對區域、群體和國家/地區的具體情況進行解讀,從而提供關於外科雷射生態系統的可操作的、基於證據的觀點。
手術雷射在現代外科醫學中日益重要,它支持精準、微創治療、止血、組織選擇性以及跨多個專科的高效手術流程。其最大的發展機會在於臨床證據、安全的能量傳輸、臨床醫生的熟練程度、可靠的維護以及與影像、內視鏡、機器人手術和數位化文件的整合。不同地區的應用情況將持續存在差異,這取決於醫療基礎設施、保險報銷、監管要求、專科資源、培訓系統和服務支援。人工智慧 (AI) 透過改善規劃、指導、監測、記錄和儀器可靠性,為手術雷射的應用提供了新的可能性,但其影響取決於嚴格的檢驗、網路安全和負責任的部署。對於行業相關人員,成功的關鍵在於超越儀器功能本身,並關注其整體價值主張,包括已證實的治療效果、培訓、合規性、運轉率、安全管理以及特定手術的性能。手術雷射應被視為精準手術的基礎技術,其臨床可靠性、安全性和工作流程相容性是決定其長期應用的關鍵因素。
The Surgical Lasers Market is projected to grow by USD 4.26 billion at a CAGR of 6.19% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 2.80 billion |
| Estimated Year [2026] | USD 2.90 billion |
| Forecast Year [2032] | USD 4.26 billion |
| CAGR (%) | 6.19% |
Surgical lasers are becoming central to precision medicine across ophthalmology, dermatology, urology, gynecology, dentistry, oncology, cardiovascular procedures, ENT, and minimally invasive surgery. By delivering concentrated light energy through wavelengths such as CO2, Nd:YAG, diode, erbium, excimer, holmium, thulium, and femtosecond systems, these devices enable cutting, ablation, coagulation, vaporization, lithotripsy, photocoagulation, and tissue resurfacing with high procedural control. Their clinical value is closely tied to reduced bleeding, improved visualization, shorter incision paths, lower thermal spread when appropriately selected, and expanding compatibility with endoscopic, robotic, and image-guided platforms. Demand is being shaped by rising surgical volumes, aging populations, higher prevalence of cataracts, benign prostatic hyperplasia, kidney stones, skin lesions, glaucoma, diabetic retinopathy, and chronic eye disorders, as well as patient preference for less invasive treatments and faster recovery. Regulatory oversight, laser safety standards, clinician training, wavelength-specific indications, eye and plume protection, and maintenance quality remain decisive factors in adoption. The surgical lasers landscape is therefore defined not only by device innovation but also by evidence-based clinical utility, procedural workflow integration, and the ability of healthcare systems to support safe, efficient laser-enabled interventions.
The surgical lasers landscape is undergoing transformative shifts as healthcare providers move from standalone energy devices toward connected, procedure-specific platforms. Minimally invasive and office-based procedures are increasing the relevance of compact diode and solid-state laser systems, while femtosecond and excimer lasers continue to support high-precision ophthalmic applications. In urology, laser lithotripsy and prostate procedures are benefiting from wavelength optimization, fiber miniaturization, Moses-effect pulse modulation, thulium fiber laser adoption, and improved energy delivery. In dermatology and aesthetic surgery, fractional delivery, pulse modulation, cooling technologies, and skin-type-aware protocols are improving procedure customization. Hospitals and ambulatory surgical centers are prioritizing systems that reduce procedure time, support reproducible outcomes, and align with infection control and equipment utilization policies. At the same time, procurement decisions are becoming more sophisticated, considering total cost of ownership, consumable fibers, service contracts, training requirements, laser plume management, eye-safety controls, and compatibility with existing endoscopes or imaging systems. The shift toward value-based care is also pushing suppliers and care providers to demonstrate clinical benefits through peer-reviewed evidence, real-world performance, and measurable improvements in surgical efficiency, complication reduction, and patient experience.
Artificial intelligence is beginning to influence surgical lasers through planning, guidance, monitoring, and workflow optimization rather than replacing clinician decision-making. AI-enabled image analysis can support preoperative assessment in ophthalmology, dermatology, and oncology by helping identify tissue boundaries, lesion characteristics, vascular patterns, or treatment zones. Intraoperative decision-support tools may improve energy delivery by combining imaging, sensor feedback, and procedural parameters to assist with tissue recognition, thermal control, plume detection, and safety alerts. For laser platforms integrated with robotics or navigation systems, AI can enhance precision by supporting trajectory planning, tremor compensation, depth estimation, and automated documentation. Predictive maintenance algorithms can analyze device performance logs, fiber-use patterns, calibration status, and error codes to reduce downtime and improve equipment reliability. However, adoption is constrained by validation requirements, cybersecurity obligations, explainability expectations, regulatory scrutiny for software as a medical device, and the need for diverse clinical datasets that reflect different populations, skin types, ocular characteristics, and procedure types. The cumulative impact of AI in surgical lasers is expected to be strongest where it improves safety, standardizes technique, reduces variability, supports auditability, and provides defensible evidence for clinical quality management.
In Asia-Pacific, surgical laser adoption is supported by expanding hospital infrastructure, high cataract and refractive surgery volumes, rapid growth in medical tourism, and increasing access to dermatology, dental, ENT, and urology procedures across China, India, Japan, South Korea, Australia, and ASEAN economies. North America remains highly procedure-driven, with strong use of ophthalmic, dermatologic, urologic, gynecologic, and minimally invasive surgical lasers, supported by advanced outpatient surgical settings, reimbursement pathways for selected procedures, established laser safety practices, and rigorous regulatory compliance. Latin America is seeing gradual uptake as private healthcare networks, aesthetic medicine centers, dental practices, and specialty clinics invest in laser-based systems, though affordability, training access, financing, and equipment servicing remain important constraints. Europe benefits from mature hospital systems, strong clinical guideline adoption, and regulatory emphasis on safety, clinical evaluation, post-market surveillance, and evidence-based device performance, while demand is reinforced by ophthalmology, gynecology, dermatology, ENT, and urology applications. The Middle East is advancing through specialty hospital development, premium surgical care, digital operating room investment, and government-led healthcare modernization, with demand concentrated in urban centers and medical tourism hubs. Africa presents a more uneven landscape, where leading private hospitals and tertiary centers deploy laser technologies for eye care, urology, dentistry, and dermatology, while broader expansion depends on clinician training, infrastructure reliability, financing models, referral pathways, and access to maintenance services.
ASEAN markets are increasingly relevant for surgical lasers because of growing private hospital networks, rising medical tourism, urban specialty clinics, and expanding ophthalmology, dentistry, urology, and aesthetic procedure capacity in countries such as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. The GCC demonstrates strong demand for advanced laser-enabled surgery through investments in specialty hospitals, digital operating rooms, premium dermatology, ophthalmology, gynecology, and urology services, supported by healthcare diversification strategies and high-acuity urban care models. The European Union emphasizes regulatory compliance, clinical evidence, medical device traceability, and post-market surveillance under strengthened medical device rules, making adoption closely linked to safety certification, performance monitoring, and hospital procurement standards. BRICS countries represent a diverse adoption environment: China and India offer large procedure volumes, expanding hospital capacity, and growing manufacturing ecosystems; Brazil and South Africa show demand through private specialty care and urban tertiary hospitals; and Russia maintains demand in ophthalmology, urology, dermatology, and hospital-based surgery despite procurement and access variability. G7 countries generally show higher integration of surgical lasers into established specialties, supported by trained clinicians, advanced ambulatory care, clinical governance, and stronger quality-control systems. NATO-aligned healthcare systems, while not a medical procurement bloc, often share emphasis on healthcare resilience, interoperability, clinical safety, emergency preparedness, and advanced hospital infrastructure, which can indirectly support adoption of high-precision surgical technologies where national reimbursement and regulatory pathways permit.
The United States shows broad surgical laser utilization across ophthalmology, dermatology, urology, gynecology, dentistry, ENT, and outpatient surgery, supported by specialist density, ambulatory surgical centers, regulatory oversight, and strong clinical training ecosystems. Canada demonstrates steady adoption in hospital and specialty clinic settings, with procurement influenced by provincial healthcare priorities, safety standards, technology assessment, and access considerations across urban and remote regions. Mexico benefits from private healthcare growth, cross-border care, ophthalmology, dentistry, and aesthetic procedures, although capital access, training availability, and service coverage affect wider penetration. Brazil is the leading Latin American opportunity for laser-based surgery due to its large private care sector, dermatology strength, ophthalmology demand, dental service capacity, and growing urology applications. The United Kingdom integrates surgical lasers through public hospitals and private clinics, with adoption shaped by evidence appraisal, budget prioritization, clinical governance, and regulated patient safety practices. Germany is a technologically advanced environment with strong hospital infrastructure, precision surgery practices, and use across ophthalmology, urology, ENT, gynecology, and dermatology. France emphasizes regulated adoption through hospital procurement, clinical quality standards, and specialist-led use in eye care, skin treatment, gynecology, ENT, and urology. Russia maintains demand in laser ophthalmology and hospital-based procedures, though access to advanced systems can vary by region, procurement channel, and service capability. Italy and Spain both show established use in ophthalmology, dermatology, urology, dentistry, and gynecology, supported by specialist practice networks and demand for minimally invasive care. China is advancing rapidly through expanding hospital capacity, domestic device development, high surgical volumes, and strong ophthalmic, urologic, dental, and aesthetic procedure demand. India combines large unmet surgical needs with growing private hospital networks, medical tourism, and expanding use of lasers in ophthalmology, urology, dentistry, dermatology, and gynecology. Japan remains a high-quality, technology-focused environment with strong ophthalmology, dermatology, endoscopic surgery, and minimally invasive surgical practice. Australia uses surgical lasers across advanced hospital and specialty clinic networks, with adoption influenced by clinician training, regulatory compliance, reimbursement access, and geographic service delivery. South Korea is highly active in dermatology, aesthetic medicine, ophthalmology, dentistry, and advanced surgical care, supported by technology-oriented hospitals, medical tourism, and strong patient demand for minimally invasive procedures.
Industry leaders should prioritize evidence-led product strategies that align each surgical laser platform with clear clinical indications, validated safety profiles, wavelength-specific use cases, and measurable workflow advantages. Manufacturers and distributors should invest in clinician education, simulation-based training, laser safety certification support, plume management guidance, and application-specific protocols to reduce variability and strengthen adoption. Healthcare providers should evaluate devices through total cost of ownership, fiber and consumable requirements, maintenance responsiveness, calibration needs, plume evacuation requirements, eye-safety controls, integration with endoscopic or imaging systems, and staff competency requirements. Product development teams should focus on compact footprints, intuitive interfaces, pulse and energy precision, tissue-specific presets, cooling and smoke management compatibility, fiber durability, and digital documentation capabilities. Organizations pursuing AI-enabled laser systems should build transparent validation frameworks, cybersecurity controls, bias assessment processes, human oversight models, and regulatory-ready evidence packages. Regional strategies should account for reimbursement structures, infrastructure maturity, procedure mix, local training capacity, and service networks rather than relying on a single global commercialization model. Above all, leaders should position surgical lasers as part of a broader precision surgery ecosystem that combines device performance, procedural training, patient safety, and post-procedure outcome tracking.
This executive summary is developed using a structured secondary research methodology focused on verified, data-backed industry intelligence. The approach synthesizes information from regulatory agencies, recognized medical device safety standards, clinical practice guidelines, peer-reviewed medical literature, public health statistics, hospital procurement considerations, professional society resources, and documented adoption trends across surgical specialties. Analysis emphasizes clinical applications, technology evolution, regional healthcare infrastructure, regulatory context, procedure workflows, and adoption enablers and barriers. The methodology excludes unsupported projections, market sizing, market share, and forecasting, and instead focuses on observable drivers such as disease burden, surgical technique evolution, outpatient care expansion, laser safety requirements, training needs, device maintenance, and technology integration. Regional, group, and country insights are interpreted through healthcare access, specialty care capacity, regulatory maturity, reimbursement context, and service infrastructure to provide a practical, evidence-oriented view of the surgical lasers ecosystem.
Surgical lasers are increasingly important to modern procedural care because they support precision, minimally invasive treatment, hemostasis, tissue selectivity, and efficient surgical workflows across multiple specialties. The strongest opportunities are linked to clinical evidence, safe energy delivery, clinician proficiency, reliable servicing, and integration with imaging, endoscopy, robotics, and digital documentation. Regional adoption will continue to vary according to healthcare infrastructure, reimbursement, regulatory expectations, specialty access, training capacity, and service support. Artificial intelligence adds a new layer of potential by improving planning, guidance, monitoring, documentation, and equipment reliability, but its impact depends on rigorous validation, cybersecurity, and responsible implementation. For industry stakeholders, success will depend on moving beyond device features toward holistic value: proven outcomes, training, compliance, uptime, safety management, and procedure-specific performance. Surgical lasers are best understood as enabling technologies within precision surgery, where clinical trust, safety, and workflow relevance determine long-term adoption.